Review Article| Volume 30, ISSUE 2, P165-177, May 2020

Liquid Biopsies Using Circulating Tumor DNA in Non-Small Cell Lung Cancer


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.

      Content published before 2002 is available via pay-per-view purchase only.


      Subscribe to Thoracic Surgery Clinics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Herbst R.S.
        • Morgensztern D.
        • Boshoff C.
        The biology and management of non-small cell lung cancer.
        Nature. 2018;
        • Pellini Ferreira B.
        • Morgensztern D.
        Cell-free DNA in cancer diagnosis and follow-up.
        in: Govindan R. Devarakonda S. Cancer genomics for the clinician. Demos Medical Publishing, New York2019: 115-126
        • Diaz L.A.
        • Bardelli A.
        Liquid biopsies: genotyping circulating tumor DNA.
        J Clin Oncol. 2014; 32: 579-586
        • Sacher A.G.
        • Komatsubara K.M.
        • Oxnard G.R.
        Application of plasma genotyping technologies in non–small cell lung cancer: a practical review.
        J Thorac Oncol. 2017; 12: 1344-1356
        • Rolfo C.
        • Manca P.
        • Salgado R.
        • et al.
        Multidisciplinary molecular tumour board: a tool to improve clinical practice and selection accrual for clinical trials in patients with cancer.
        ESMO Open. 2018; 3: e000398
        • Jahr S.
        • Hentze H.
        • Englisch S.
        • et al.
        DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells.
        Cancer Res. 2001; 61: 1659-1665
        • Choi J.J.
        • Reich C.F.
        • Pisetsky D.S.
        The role of macrophages in the in vitro generation of extracellular DNA from apoptotic and necrotic cells.
        Immunology. 2005; 115: 55-62
        • Chin R.I.
        • Chen K.
        • Usmani A.
        • et al.
        Detection of solid tumor molecular residual disease (MRD) using circulating tumor DNA (ctDNA).
        Mol Diagn Ther. 2019; 23: 311-331
        • Chaudhuri A.A.
        • Chabon J.J.
        • Lovejoy A.F.
        • et al.
        Early detection of molecular residual disease in localized lung cancer by circulating tumor DNA profiling.
        Cancer Discov. 2017; 7: 1394-1403
        • Dudley J.C.
        • Schroers-Martin J.
        • Lazzareschi D.V.
        • et al.
        Detection and surveillance of bladder cancer using urine tumor DNA.
        Cancer Discov. 2018; : 10
        • Springer S.U.
        • Chen C.-H.
        • Rodriguez Pena M.D.C.
        • et al.
        Non-invasive detection of urothelial cancer through the analysis of driver gene mutations and aneuploidy.
        Elife. 2018; 7: 1-27
        • De Mattos-Arruda L.
        • Mayor R.
        • Ng C.K.Y.
        • et al.
        Cerebrospinal fluid-derived circulating tumour DNA better represents the genomic alterations of brain tumours than plasma.
        Nat Commun. 2015; 6: 1-6
        • Husain H.
        • Nykin D.
        • Bui N.
        • et al.
        Cell-free DNA from ascites and pleural effusions: molecular insights into genomic aberrations and disease biology.
        Mol Cancer Ther. 2017; 16: 948-955
        • Chaudhuri A.A.
        • Binkley M.S.
        • Osmundson E.C.
        • et al.
        Predicting radiotherapy responses and treatment outcomes through analysis of circulating tumor DNA.
        Semin Radiat Oncol. 2015; 25: 305-312
        • Corcoran R.B.
        • Chabner B.A.
        Application of cell-free DNA analysis to cancer treatment.
        N Engl J Med. 2018; 379: 1754-1765
        • Yao W.
        • Mei C.
        • Nan X.
        • et al.
        Evaluation and comparison of in vitro degradation kinetics of DNA in serum, urine and saliva: a qualitative study.
        Gene. 2016; 590: 142-1488
        • Alborelli I.
        • Generali D.
        • Jermann P.
        • et al.
        Cell-free DNA analysis in healthy individuals by next-generation sequencing: a proof of concept and technical validation study.
        Cell Death Dis. 2019; 10: 534
        • Stroun M.
        • Anker P.
        • Lyautey J.
        • et al.
        Isolation and characterization of DNA from the plasma of cancer patients.
        Eur J Cancer Clin Oncol. 1987; 23: 707-712
        • Hu Y.
        • Ulrich B.C.
        • Supplee J.
        • et al.
        False-positive plasma genotyping due to clonal hematopoiesis.
        Clin Cancer Res. 2018; 24: 4437-4443
        • El Messaoudi S.
        • Rolet F.
        • Mouliere F.
        • et al.
        Circulating cell free DNA: preanalytical considerations.
        Clin Chim Acta. 2013;
        • Rolfo C.
        • Mack P.C.
        • Scagliotti G.V.
        • et al.
        Liquid biopsy for advanced non-small cell lung cancer (NSCLC): a statement paper from the IASLC.
        J Thorac Oncol. 2018;
        • Parpart-Li S.
        • Bartlett B.
        • Popoli M.
        • et al.
        The effect of preservative and temperature on the analysis of circulating tumor DNA.
        Clin Cancer Res. 2017; 23: 2471-2477
        • Newton C.R.
        • Graham A.
        • Heptinstall L.E.
        • et al.
        Analysis of any point mutation in DNA. The amplification refractory mutation system (ARMS).
        Nucleic Acids Res. 1989; 17: 2503-2516
        • Malapelle U.
        • Sirera R.
        • Jantus-Lewintre E.
        • et al.
        Profile of the Roche cobas® EGFR mutation test v2 for non-small cell lung cancer.
        Expert Rev Mol Diagn. 2017;
        • Mok T.
        • Wu Y.L.
        • Lee J.S.
        • et al.
        Detection and dynamic changes of EGFR mutations from circulating tumor DNA as a predictor of survival outcomes in NSCLC Patients treated with first-line intercalated erlotinib and chemotherapy.
        Clin Cancer Res. 2015;
        • Vogelstein B.
        • Kinzler K.W.
        Digital PCR.
        Genetics. 1999; 96: 9236-9241
        • Garcia-Murillas I.
        • Schiavon G.
        • Weigelt B.
        • et al.
        Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer.
        Sci Transl Med. 2015; 7: 1-7
        • Oxnard G.R.
        • Thress K.S.
        • Alden R.S.
        • et al.
        Association between plasma genotyping and outcomes of treatment with osimertinib (AZD9291) in advanced non-small-cell lung cancer.
        J Clin Oncol. 2016; 34: 3375-3382
        • Sacher A.G.
        • Paweletz C.
        • Dahlberg S.E.
        • et al.
        Prospective validation of rapid plasma genotyping as a sensitive and specific tool for guiding lung cancer care.
        JAMA Oncol. 2016; 2: 1014-1022
        • Kinde I.
        • Papadopoulos N.
        • Kinzler K.W.
        • et al.
        FAST-SeqS: a simple and efficient method for the detection of aneuploidy by massively parallel sequencing.
        PLoS One. 2012; 7: 1-8
        • Leighl N.B.
        • Page R.D.
        • Raymond V.M.
        • et al.
        Clinical utility of comprehensive cell-free DNA analysis to identify genomic biomarkers in patients with newly diagnosed metastatic non-small cell lung cancer.
        Clin Cancer Res. 2019;
        • Abbosh C.
        • Birkbak N.J.
        • Swanton C.
        Early stage NSCLC: challenges to implementing ctDNA-based screening and MRD detection.
        Nat Rev Clin Oncol. 2018;
        • Newman A.M.
        • Lovejoy A.F.
        • Klass D.M.
        • et al.
        Integrated digital error suppression for improved detection of circulating tumor DNA.
        Nat Biotechnol. 2016; 34: 547-555
        • Shagin D.A.
        • Shagina I.A.
        • Zaretsky A.R.
        • et al.
        A high-throughput assay for quantitative measurement of PCR errors.
        Sci Rep. 2017; 7: 1-11
        • Lindeman N.I.
        • Cagle P.T.
        • Aisner D.L.
        • et al.
        Updated molecular testing guideline for the selection of lung cancer patients for treatment with targeted tyrosine kinase inhibitors: guideline from the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology.
        Arch Pathol Lab Med. 2018;
        • Zill O.A.
        • Banks K.C.
        • Fairclough S.R.
        • et al.
        The landscape of actionable genomic alterations in cell-free circulating tumor DNA from 21,807 advanced cancer patients.
        Clin Cancer Res. 2018; 24: 3528-3538
        • Abbosh C.
        • Birkbak N.J.
        • Wilson G.A.
        • et al.
        Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution.
        Nature. 2017; 545: 446-451
        • Thress K.S.
        • Brant R.
        • Carr T.H.
        • et al.
        EGFR mutation detection in ctDNA from NSCLC patient plasma: a cross-platform comparison of leading technologies to support the clinical development of AZD9291.
        Lung Cancer. 2015; 90: 509-515
        • Soria J.C.
        • Ohe Y.
        • Vansteenkiste J.
        • et al.
        Osimertinib in untreated EGFR-Mutated advanced non-small-cell lung cancer.
        N Engl J Med. 2018;
        • Siravegna G.
        • Marsoni S.
        • Siena S.
        • et al.
        Integrating liquid biopsies into the management of cancer.
        Nat Rev Clin Oncol. 2017;
      1. Hasan MM, Patel J, Johnson I, et al. Tracking minimal residual disease in post-operative cell-free DNA using MSK-ACCESS [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 1387.

        • Gale D.
        • Lawson A.R.J.
        • Howarth K.
        • et al.
        Development of a highly sensitive liquid biopsy platform to detect clinically-relevant cancer mutations at low allele fractions in cellfree DNA.
        PLoS One. 2018;
        • Chabon J.J.
        • Simmons A.D.
        • Lovejoy A.F.
        • et al.
        Analytical and clinical validation of a digital sequencing panel for quantitative, highly accurate evaluation of cell-free circulating tumor DNA.
        Clin Cancer Res. 2017; 545: 60-65
        • Sabari J.K.
        • Offin M.
        • Stephens D.
        • et al.
        A prospective study of circulating tumor DNA to guide matched targeted therapy in lung cancers.
        J Natl Cancer Inst. 2019; 111: 575-583
        • Gutierrez M.E.
        • Choi K.
        • Lanman R.B.
        • et al.
        Genomic profiling of advanced non–small cell lung cancer in community settings: gaps and opportunities.
        Clin Lung Cancer. 2017;
        • Ettinger D.S.
        • Wood D.E.
        • Aisner D.L.
        • et al.
        Non–small cell lung cancer, version 5.2017, NCCN clinical practice guidelines in oncology.
        J Natl Compr Canc Netw. 2017; 15: 504-535
        • Chong C.R.
        • Jänne P.A.
        The quest to overcome resistance to EGFR-targeted therapies in cancer.
        Nat Med. 2013;
        • Jenkins S.
        • Yang J.C.H.
        • Ramalingam S.S.
        • et al.
        Plasma ctDNA analysis for detection of the EGFR T790M mutation in patients with advanced non–small cell lung cancer.
        J Thorac Oncol. 2017;
        • Gandara D.R.
        • Paul S.M.
        • Kowanetz M.
        • et al.
        Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab.
        Nat Med. 2018;
        • Fehrenbacher L.
        • Spira A.
        • Ballinger M.
        • et al.
        Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial.
        Lancet. 2016;
        • Rittmeyer A.
        • Barlesi F.
        • Waterkamp D.
        • et al.
        Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial.
        Lancet. 2017; 389: 255-265
        • Goldberg S.B.
        • Narayan A.
        • Kole A.J.
        • et al.
        Early assessment of lung cancer immunotherapy response via circulating tumor DNA.
        Clin Cancer Res. 2018; 24: 1872-1880
        • Nishino M.
        • Jagannathan J.P.
        • Ramaiya N.H.
        • et al.
        Revised RECIST guideline version 1.1: what oncologists want to know and what radiologists need to know.
        Am J Roentgenol. 2010; 195: 281-289
        • Kim E.Y.
        • Cho E.N.
        • Park H.S.
        • et al.
        Genetic heterogeneity of actionable genes between primary and metastatic tumor in lung adenocarcinoma.
        BMC Cancer. 2016;
        • Jamal-Hanjani M.
        • Hackshaw A.
        • Ngai Y.
        • et al.
        Tracking genomic cancer evolution for precision medicine: the lung TRACERx study.
        PLoS Biol. 2014; 12: 1-7
        • Jamal-Hanjani M.
        • Wilson G.A.
        • McGranahan N.
        • et al.
        Tracking the evolution of non–small-cell lung cancer.
        N Engl J Med. 2017; 376: 2109-2121
        • Thress K.S.
        • Paweletz C.P.
        • Felip E.
        • et al.
        Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M.
        Nat Med. 2015; 21: 560-562
        • Phallen J.
        • Sausen M.
        • Adleff V.
        • et al.
        Direct detection of early-stage cancers using circulating tumor DNA.
        Sci Transl Med. 2017; 9: 1-12
        • Chabon J.J.
        • Simmons A.D.
        • Lovejoy A.F.
        • et al.
        Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients.
        Nat Commun. 2016; 7: 1-14
        • Tie J.
        • Wang Y.
        • Tomasetti C.
        • et al.
        Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer.
        Sci Transl Med. 2016; 8: 1-10
        • Swanton C.
        • Venn O.
        • Aravanis A.
        • et al.
        Prevalence of clonal hematopoiesis of indeterminate potential (CHIP) measured by an ultra-sensitive sequencing assay: exploratory analysis of the circulating cancer genome atlas (CCGA) study.
        J Clin Oncol. 2018; 36: 12003
        • Genovese G.
        • Kähler A.K.
        • Handsaker R.E.
        • et al.
        Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence.
        N Engl J Med. 2014; 371: 2477-2487
        • Jaiswal S.
        • Fontanillas P.
        • Flannick J.
        • et al.
        Age-related clonal hematopoiesis associated with adverse outcomes.
        N Engl J Med. 2014; 371: 2488-2498
        • Steensma D.P.
        • Bejar R.
        • Jaiswal S.
        • et al.
        Perspective: clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes.
        Blood. 2018; 126: 9-17
        • Acuna-Hidalgo R.
        • Sengul H.
        • Steehouwer M.
        • et al.
        Ultra-sensitive sequencing identifies high prevalence of clonal hematopoiesis-associated mutations throughout adult life.
        Am J Hum Genet. 2017; 101: 50-64
        • Zink F.
        • Stacey S.N.
        • Norddahl G.L.
        • et al.
        Clonal hematopoiesis, with and without candidate driver mutations, is common in the elderly.
        Blood. 2017; 130: 742-752
        • Young A.L.
        • Challen G.A.
        • Birmann B.M.
        • et al.
        Clonal haematopoiesis harbouring AML-associated mutations is ubiquitous in healthy adults.
        Nat Commun. 2016; 7: 12484
        • Bronkhorst A.J.
        • Aucamp J.
        • Pretorius P.J.
        Cell-free DNA: preanalytical variables.
        Clin Chim Acta. 2015;
        • Underhill H.R.
        • Kitzman J.O.
        • Hellwig S.
        • et al.
        Fragment length of circulating tumor DNA.
        PLoS Genet. 2016; 12: 1-24
        • Mouliere F.
        • Robert B.
        • Peyrotte E.
        • et al.
        High fragmentation characterizes tumour-derived circulating DNA.
        PLoS One. 2011; 6: e23418
        • Mouliere F.
        • Chandrananda D.
        • Piskorz A.M.
        • et al.
        Enhanced detection of circulating tumor DNA by fragment size analysis.
        Sci Transl Med. 2018; 10: 1-14
        • Xu T.
        • Kang X.
        • You X.
        • et al.
        Cross-platform comparison of four leading technologies for detecting EGFR mutations in circulating tumor DNA from non-small cell lung carcinoma patient plasma.
        Theranostics. 2017; 7: 1437-1446
        • Ye M.
        • Li S.
        • Huang W.
        • et al.
        Comprehensive targeted super-deep next generation sequencing enhances differential diagnosis of solitary pulmonary nodules.
        J Thorac Dis. 2018;
        • Gettinger S.
        • Horn L.
        • Jackman D.
        • et al.
        Five-year follow-up of nivolumab in previously treated advanced non–small-cell lung cancer: results from the CA209-003 study.
        J Clin Oncol. 2018;
      2. Krebs M, Dive C, Dean EJ, et al. TARGET trial: molecular profiling of circulating tumour DNA to stratify patients to early phase clinical trials. In: JCO ASCO meeting. Chicago, June 3–7, 2016.